Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Poluzzi

Showing results (81-90 of 189) with videos related to

Pageof 19
Sort By:
Drug Safety|March 28, 2018
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting SystemsEmanuel Raschi, Anna Girardi, Elisabetta Poluzzi, et al.
International Journal of Legal Medicine|October 8, 2025
Characterizing post-mortem blood concentrations in methadone-related deathsGuido Pelletti, Valentina Giunchi, Paolo Fais, et al.
European Journal of Clinical Pharmacology|November 2, 2004
Pattern of NSAID use in the Italian general population: a questionnaire-based surveyDomenico Motola, Alberto Vaccheri, Maria Chiara Silvani, et al.
The International Journal of Neuropsychopharmacology|May 31, 2022
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting SystemMichele Fusaroli, Emanuel Raschi, Valentina Giunchi, et al.
Drug Safety|January 4, 2024
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERSMichele Fusaroli, Valentina Giunchi, Vera Battini, et al.
Vaccine|February 19, 2018
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysisJulie Mouchet, Francesco Salvo, Emanuel Raschi, et al.
American Journal of Clinical Dermatology|October 26, 2021
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Michelangelo La Placa, et al.
Kidney International Reports|September 13, 2021
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System RegistryValeria Aiello, Michele Fusaroli, Emanuel Raschi, et al.
Annals of Hematology|April 23, 2026
Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reportsEdoardo Muratore, Valentina Giunchi, Michele Fusaroli, et al.
Targeted Oncology|May 6, 2026
Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and PharmacodynamicsMonia Donati, Chiara Cancellerini, Valentina Giunchi, et al.
Pageof 19

Showing results (81-90 of 189) with videos related to

Sort By:
Pageof 19
Drug Safety|March 28, 2018
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting SystemsEmanuel Raschi, Anna Girardi, Elisabetta Poluzzi, et al.
International Journal of Legal Medicine|October 8, 2025
Characterizing post-mortem blood concentrations in methadone-related deathsGuido Pelletti, Valentina Giunchi, Paolo Fais, et al.
European Journal of Clinical Pharmacology|November 2, 2004
Pattern of NSAID use in the Italian general population: a questionnaire-based surveyDomenico Motola, Alberto Vaccheri, Maria Chiara Silvani, et al.
The International Journal of Neuropsychopharmacology|May 31, 2022
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting SystemMichele Fusaroli, Emanuel Raschi, Valentina Giunchi, et al.
Drug Safety|January 4, 2024
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERSMichele Fusaroli, Valentina Giunchi, Vera Battini, et al.
Vaccine|February 19, 2018
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysisJulie Mouchet, Francesco Salvo, Emanuel Raschi, et al.
American Journal of Clinical Dermatology|October 26, 2021
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Michelangelo La Placa, et al.
Kidney International Reports|September 13, 2021
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System RegistryValeria Aiello, Michele Fusaroli, Emanuel Raschi, et al.
Annals of Hematology|April 23, 2026
Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reportsEdoardo Muratore, Valentina Giunchi, Michele Fusaroli, et al.
Targeted Oncology|May 6, 2026
Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and PharmacodynamicsMonia Donati, Chiara Cancellerini, Valentina Giunchi, et al.
Pageof 19